About this trial
The goal of this prospective, exploratory, non-intervention, multi-center, real-world study is to investigate the predictive value of HBV pgRNA in the occurrence of long-term outcomes under antiviral therapy in patients with chronic hepatitis B.
Participants will take the necessary clinical examination and blood draw during the patient's treatment and follow-up, and all the treatment is determined by clinicians.
Eligibility criteria
Qualifiers
CHB defined as positive hepatitis B surface antigen at least 6 months, or HBV-related histological changes within 1 year if HBsAg positive less than 6 months;
Age between 18-80 years, gender is not limited；
Patients with chronic hepatitis B who have been determined by clinicians to start, or have already taken the first-line treatment {including pegylated interferon [IFN] monotherapy, a potent nucleos(t)ide analogue [NA] monotherapy, two different potent NAs combination therapy, or NA plus IFN combination therapy;
Patient who reads and signs informed consent.
Disqualifiers
Patients with malignancies other than hepatocellular carcinoma.
Trial design
Treatments tested in this trial
- nucleoside analogues or interferon
Treatment groups
Sponsors and collaborators
Wen-hong Zhang
Lead sponsor
Huashan Hospital
Sponsor institution
Shandong Provincial Hospital
Collaborator
First Affiliated Hospital Xi'an Jiaotong University
Collaborator
The Affiliated Hospital of Xuzhou Medical University
Collaborator
First Affiliated Hospital of Fujian Medical University
Collaborator
The Third People's Hospital of Taiyuan
Collaborator
The First People's Hospital of Yunnan
Collaborator
The First Affiliated Hospital of Anhui Medical University
Collaborator
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborator
The First Affiliated Hospital with Nanjing Medical University
Collaborator